Alx Oncology Stock Analysis


USD 9.79  0.79  7.47%   

The latest price rise of Alx Oncology Holdings could raise concerns from institutional investors as the firm is trading at a share price of 9.79 on 152,300 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in October. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.0. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Alx Oncology partners.
Please continue to Trending Equities.
The Alx Oncology stock analysis report makes it easy to digest most publicly released information about Alx Oncology and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Alx Oncology Stock analysis module also helps to analyze the Alx Oncology price relationship with some important fundamental indicators such as market cap and management efficiency.

Alx Oncology Stock Analysis Notes

About 13.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.03. Some equities with similar Price to Book (P/B) outperform the market in the long run. Alx Oncology Holdings recorded a loss per share of 1.86. The entity had not issued any dividends in recent years. ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company was founded in 2015 and is headquartered in South San Francisco, California. Alx Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people. For more info on Alx Oncology Holdings please contact the company at 650 466 7125 or go to

Alx Oncology Holdings Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Alx Oncology's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Alx Oncology Holdings or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Alx Oncology has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 527 K. Net Loss for the year was (93.81 M) with profit before overhead, payroll, taxes, and interest of 107 K.
Alx Oncology Holdings currently holds about 316.6 M in cash with (83.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.78.
Over 89.0% of the company shares are held by institutions such as insurance companies
Latest headline from Should Biotechnology Stock ALX Oncology Holdings Inc Be in Your Portfolio Thursday - InvestorsObserver

Alx Oncology Holdings Upcoming and Recent Events

Earnings reports are used by Alx Oncology to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Alx Oncology previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report17th of March 2022
Next Financial Report16th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End17th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Alx Oncology SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Alx Oncology prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Alx Oncology investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Alx Oncology Holdings specific information freely available to individual and institutional investors to make a timely investment decision.
10th of August 2022
Unclassified Corporate Event
8th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
16th of June 2022
Submission of Matters to a Vote of Security Holders
10th of June 2022
Unclassified Corporate Event
9th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
12th of April 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
28th of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
9th of February 2022
Unclassified Corporate Event

Alx Oncology Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Alx Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Alx Oncology Holdings backward and forwards among themselves. Alx Oncology's institutional investor refers to the entity that pools money to purchase Alx Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Venbio Partners LlcCommon Shares9.7 M78.5 M
Vivo Capital LlcCommon Shares4.2 M34.1 M
Fmr LlcCommon SharesM32.2 M
Logos Global Management LpCommon Shares3.1 M25.4 M
Orbimed Advisors LlcCommon Shares2.2 M17.7 M
Blackrock IncCommon Shares1.7 M13.4 M
Vanguard Group IncCommon Shares1.3 M10.7 M
Note, although Alx Oncology's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Alx Oncology Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 396.49 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Alx Oncology's market, we take the total number of its shares issued and multiply it by Alx Oncology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (14.77) % which means that it has lost $14.77 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (24.62) %, meaning that it created substantial loss on money invested by shareholders. Alx Oncology management efficiency ratios could be used to measure how well alx oncology holdings manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 24th of September, Alx Oncology shows the Downside Deviation of 4.99, mean deviation of 3.79, and Risk Adjusted Performance of 0.1605. Alx Oncology Holdings technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have analyzed and interpolated nineteen technical drivers for Alx Oncology Holdings, which can be compared to its rivals. Please confirm Alx Oncology Holdings information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Alx Oncology Holdings is priced correctly, providing market reflects its regular price of 9.79 per share. Given that Alx Oncology has jensen alpha of 0.7376, we suggest you to validate Alx Oncology Holdings's prevailing market performance to make sure the company can sustain itself at a future point.

Alx Oncology Holdings Price Movement Analysis

null. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Alx Oncology Holdings price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.

Alx Oncology Holdings Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alx Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alx Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Alx Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Alx Oncology Predictive Daily Indicators

Alx Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Alx Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Alx Oncology Forecast Models

Alx Oncology time-series forecasting models is one of many Alx Oncology's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Alx Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Alx Oncology Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Alx Oncology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Alx Oncology shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Alx Oncology. By using and applying Alx Oncology Stock analysis, traders can create a robust methodology for identifying Alx Oncology entry and exit points for their positions.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company was founded in 2015 and is headquartered in South San Francisco, California. Alx Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people.

Current Alx Oncology Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Alx Oncology analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Alx Oncology analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Alx Oncology Holdings current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Alx Oncology analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Alx Oncology stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Alx Oncology Holdings, talking to its executives and customers, or listening to Alx Oncology conference calls.
Alx Oncology Analyst Advice Details

Alx Oncology Stock Analysis Indicators

Alx Oncology Holdings stock analysis indicators help investors evaluate how Alx Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Alx Oncology shares will generate the highest return on investment. By understating and applying Alx Oncology stock analysis, traders can identify Alx Oncology position entry and exit signals to maximize returns.
Quick Ratio20.72
Fifty Two Week Low5.82
Shares Short Prior Month4.62M
Average Daily Volume Last 10 Day132.53k
Average Daily Volume In Three Month248.62k
Shares Percent Shares Out9.61%
Short Percent Of Float18.38%
Forward Price Earnings-3.11
Float Shares18.11M
Fifty Two Week High79.00
Enterprise Value To Ebitda-0.88
Fifty Day Average12.23
Two Hundred Day Average14.35
Please continue to Trending Equities. You can also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for analysis

When running Alx Oncology Holdings price analysis, check to measure Alx Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alx Oncology is operating at the current time. Most of Alx Oncology's value examination focuses on studying past and present price action to predict the probability of Alx Oncology's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Alx Oncology's price. Additionally, you may evaluate how the addition of Alx Oncology to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Is Alx Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine Alx Oncology value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.